Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

被引：0
|
作者：
Igor Bondarenko
Oleg A Gladkov
Reiner Elsaesser
Anton Buchner
Peter Bias
机构：
[1] State Medical Academy,Dnipropetrovsk
[2] Chelyabinsk Regional Clinical Oncology Center,undefined
[3] Teva Ratiopharm,undefined
来源：
BMC Cancer | / 13卷
关键词：
Neutropenia; Febrile neutropenia; Breast cancer; Recombinant granulocyte-colony stimulating factor; Lipegfilgrastim; Pegfilgrastim;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
    Bondarenko, Igor
    Gladkov, Oleg A.
    Elsaesser, Reiner
    Buchner, Anton
    Bias, Peter
    BMC CANCER, 2013, 13
  • [2] Analysis of ANC recovery from a Phase III study of lipegfilgrastim versus pegfilgrastim in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
    Bondarenko, I.
    Bias, P.
    Elsaesser, R.
    Buchner, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S434 - S435
  • [3] EFFICACY AND SAFETY OF LIPEGFILGRASTIM COMPARED WITH PEGFILGRASTIM IN PATIENTS WITH BREAST CANCER WHO ARE RECEIVING CHEMOTHERAPY
    Udo, M.
    Bondarenko, I.
    Gladkov, O.
    Elaesser, R.
    Buchner, A.
    Bias, P.
    HAEMATOLOGICA, 2012, 97 : 553 - 553
  • [4] A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel
    Gladkov, Oleg
    Moiseyenko, Vladimir
    Bondarenko, Igor N.
    Shparyk, Yaroslav
    Barash, Steve
    Adar, Liat
    Avisar, Noa
    ONCOLOGIST, 2016, 21 (01): : 7 - 15
  • [5] Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy.
    Bondarenko, Igor
    Gladkov, Oleg
    Elaesser, Reiner
    Buchner, Anton
    Bias, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Efficacy and Safety of Balugrastim Compared With Pegfilgrastim in Patients With Breast Cancer Receiving Chemotherapy
    Volovat, Constantin
    Gladkov, Oleg A.
    Bondarenko, Igor M.
    Barash, Steve
    Buchner, Anton
    Bias, Peter
    Adar, Liat
    Avisar, Noa
    CLINICAL BREAST CANCER, 2014, 14 (02) : 101 - 108
  • [7] Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy
    Volovat, Constantin D.
    Gladkov, Oleg
    Bondarenko, Igor
    Barash, Steven
    Buchner, Anton
    Avisar, Noa
    Bias, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] EFFICACY AND SAFETY OF BALUGRASTIM COMPARED WITH PEGFILGRASTIM IN PATIENTS WITH BREAST CANCER WHO ARE RECEIVING CHEMOTHERAPY
    Udo, M.
    Volovat, C.
    Gladkov, O.
    Bondarenko, I.
    Barash, S.
    Buchner, A.
    Avisar, N.
    Bias, P.
    HAEMATOLOGICA, 2012, 97 : 47 - 47
  • [9] Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study
    Gladkov, Oleg A.
    Buchner, Anton
    Bias, Peter
    Mueller, Udo
    Elsaesser, Reiner
    SUPPORTIVE CARE IN CANCER, 2016, 24 (01) : 395 - 400
  • [10] CHEMOTHERAPY-ASSOCIATED TREATMENT BURDEN IN BREAST CANCER PATIENTS RECEIVING LIPEGFILGRASTIM OR PEGFILGRASTIM: SECONDARY EFFICACY DATA FROM A PHASE III STUDY
    Gladkov, O.
    Buchner, A.
    Bias, P.
    Mueller, U.
    Elsaesser, R.
    HAEMATOLOGICA, 2013, 98 : 426 - 426
12345